Hold ABBV at current weight; do not add at $266.00 as breakout remains unconfirmed
Hold is the highest-probability synthesis of the ABBV debate. The existing position should be preserved because the uptrend and catalyst sequence are intact—Q1 2026 revenue was $15.0B (+12.4%), adjusted EPS was $2.65, FY2025 revenue was $61.16B (+8.6%), forward P/E was approximately 16.3x, and annual free cash flow was $17.8B. However, resistance at $266.60 is not confirmed, and a 25-33% add at $266 would risk roughly $29 per share to $237 while offering only $14 to $280 before dividends. ABBV should neither be chased into resistance nor reduced while its structural trend, cash generation, dividend, and catalysts remain intact.
| Position | Action |
|---|---|
| Sustained move above $266.60 for 2-3 sessions with above-average volume | Add 10-15% of intended exposure |
| Pullback to $245-$252 | Add 10-15% of intended exposure |
| Price reaches $278-$280 | Trim 25-30% of position |
| Close below $245 | Reassess position |
| Core mental stop | $237 |
AbbVie has completed its post-Humira transformation and emerged as a more diversified, profitable, and defensible business with multiple growth franchises, cheap forward valuation metrics, and a constructive macro backdrop for defensive compounders.
| Indicator | Value | Signal |
|---|---|---|
| Close | $265.97 | neutral |
| 10 EMA | $253.94 | bullish |
| 50 SMA | $245.65 | bullish |
| 200 SMA | $223.24 | bullish |
| RSI (14) | 67.69 | bullish |
| MACD | 2.67 | bullish |
| MACD Signal | 1.90 | bullish |
| MACD Histogram | +0.76 | bullish |
| Bollinger Upper Band | $266.60 | neutral |
| Bollinger Middle Band (20 SMA) | $252.77 | bullish |
| Bollinger Lower Band | $238.94 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $245-$252
Then: Add 10-15% of intended exposure
Multiple growth franchises are multiplying beyond initial pipeline expectations
↩ rebuts: “Pipeline concentration risk argument”
EV: +5.8% to $275–$280 on confirmed breakout above $266.60 · concedes: Epcoritamab Phase 3 DLBCL miss is a pipeline expansion headwind (though commercial revenue line is intact); ABBV has lagged S&P 500 over trailing 6 months (+9.7% vs. +13.5%); Negative stockholders' equity exists (driven by $63B cumulative buybacks and Allergan amortization, not operating losses); Net Debt/EBITDA of 3.5x is elevated relative to some peers; Trailing GAAP P/E of 74.9x appears expensive on surface optics
ABBV is a "Show Me" story trading at "Trust Me" multiples — the stock is overextended, requires perfect execution across seven concurrent catalysts, and the downside scenarios are far more numerous and severe than the upside.
· concedes: Simply Wall St. DCF-based upside exists and market-based multiples may look stretched rather than definitively overvalued; ABBV does have real growth drivers in Skyrizi/Rinvoq and a legitimate neuroscience franchise; The 66% rally from April 2025 lows represents real transformation progress; AB InBev leverage comparison is fair — pharma leverage norms differ from industrial companies; The 2.5:1 risk/reward cited by the bull is achievable if all catalysts materialize
→ vs conservative: $0.63 below upper Bollinger Band at $266.60 is not failed breakout but breakout in progress; waiting for confirmation means chasing $270+ with compressed risk/reward
→ vs conservative: "Pullback to $245-$252" contingency has meaningfully below 50% probability given PEG 0.41, expanding MACD histogram, and $12.7B neuroscience franchise re-rating in progress
→ vs conservative: Conservative risk/reward framing of "$12 risk vs $9-14 upside" ignores 6-12 month structural position through re-rating event with $290-300 target (10-15% additional return)
→ vs neutral: "Let's see what happens" neutral stance is most dangerous in this setup; momentum trades confirmed by every technical indicator, fundamental metric, and institutional flow data cost the most when waiting for confirmation
→ vs conservative: Hold-without-add decision is a bet ABBV will mean-revert before it trends, with data overwhelmingly indicating the opposite given catalyst calendar and momentum signature
→ vs conservative: Not adding while maintaining full exposure forfeits upside without reducing downside risk; better to add tranche that improves cost basis while existing position provides downside cushion
| bullish |
| ATR (14) | $6.16 | neutral |
| VWMA | $249.72 | bullish |
Support: 253.94 · 252.77 · 245.65 · 238.94 | Resistance: 266.6 · 270
ABBV is in a confirmed uptrend across all timeframes with price +4.7% above the 10 EMA, +8.3% above the 50 SMA, and +19.1% above the 200 SMA. The 2026-08-19 session produced a strong bullish reversal with price closing $0.63 below the upper Bollinger Band at $266.60—a breakout attempt that remains unconfirmed. RSI at 67.69 indicates strong momentum without overbought conditions, while MACD at 2.67 with expanding histogram confirms accelerating upside. Volume of 5,492,517 shares and VWMA at $249.72 (price +6.5% above) confirm the breakout has volume conviction. Near-term resistance is $266.60; key supports are $253.94 (10 EMA), $252.77 (20 SMA), and $245.65 (50 SMA).
Market Cap
$470B
Share Price (approx)
~$266
P/E (TTM)
74.9x
Forward P/E
16.3x
PEG Ratio
0.41
P/B
-79.2x
EV/EBITDA
~16.5x
Dividend Yield
2.67%
Beta
0.28
52W Range
$190.75 – $267.47
50D MA
$245.60
200D MA
$225.89
Revenue (2022)
$58.05B
Revenue (2023)
$54.32B
Revenue (2024)
$56.33B
Revenue (2025)
$61.16B
Revenue (TTM)
$64.4B
Revenue Growth (2025)
+8.6%
Gross Profit (2022)
$40.6B
Gross Profit (2023)
$33.9B
Gross Profit (2024)
$39.4B
Gross Profit (2025)
$43.0B
Gross Margin
~70%
Operating Income (2022)
$18.8B
Operating Income (2023)
$13.5B
Operating Income (2024)
$11.9B
Operating Income (2025)
$20.1B
Operating Margin
40.0%
EBITDA (2022)
$24.2B
EBITDA (2023)
$17.2B
EBITDA (2024)
$14.9B
EBITDA (2025)
$17.6B
EBITDA (TTM)
$30.8B
Net Income - Continuing (2022)
$11.8B
Net Income - Continuing (2023)
$4.9B
Net Income - Continuing (2024)
$4.3B
Net Income - Continuing (2025)
$4.2B
Net Income (TTM)
$6.3B
Diluted EPS (2022)
$6.63
Diluted EPS (2023)
$2.72
Diluted EPS (2024)
$2.39
Diluted EPS (2025)
$2.37
EPS (TTM)
$3.55
Forward EPS
$16.28
Normalized EPS Power
~$16+
R&D
$9.1B
SG&A
$14.0B
D&A
$8.1B
Special Charges (2025)
$5.1B
Special Charges (2024)
$2.8B
Effective Tax Rate (2022)
12.1%
Effective Tax Rate (2025)
35.8%
Total Assets (2022)
$138.8B
Total Assets (2023)
$134.7B
Total Assets (2024)
$135.2B
Total Assets (2025)
$134.0B
Total Debt (2022)
$63.3B
Total Debt (2023)
$59.4B
Total Debt (2024)
$67.1B
Total Debt (2025)
$67.5B
Net Debt (2022)
$54.1B
Net Debt (2023)
$46.6B
Net Debt (2024)
$61.6B
Net Debt (2025)
$62.3B
Net Debt/EBITDA
~3.5x
Stockholders' Equity (2022)
$17.3B
Stockholders' Equity (2023)
$10.4B
Stockholders' Equity (2024)
$3.3B
Stockholders' Equity (2025)
-$3.3B
Goodwill + Intangibles (2022)
$99.6B
Goodwill + Intangibles (2023)
$87.9B
Goodwill + Intangibles (2024)
$95.0B
Goodwill + Intangibles (2025)
$88.3B
Cash & Equivalents (2022)
$9.2B
Cash & Equivalents (2023)
$12.8B
Cash & Equivalents (2024)
$5.5B
Cash & Equivalents (2025)
$5.2B
Current Ratio
0.81
ROA
10.5%
Operating Cash Flow (2022)
$24.9B
Operating Cash Flow (2023)
$22.8B
Operating Cash Flow (2024)
$18.8B
Operating Cash Flow (2025)
$19.0B
Capital Expenditure (2022)
-$0.7B
Capital Expenditure (2023)
-$0.8B
Capital Expenditure (2024)
-$1.0B
Capital Expenditure (2025)
-$1.2B
Free Cash Flow (2022)
$24.2B
Free Cash Flow (2023)
$22.1B
Free Cash Flow (2024)
$17.8B
Free Cash Flow (2025)
$17.8B
FCF Yield
~3.6%
Dividends Paid (2022)
-$10.0B
Dividends Paid (2023)
-$10.5B
Dividends Paid (2024)
-$11.0B
Dividends Paid (2025)
-$11.7B
Dividend Coverage (FCF/Div)
~1.5x
Buybacks (2022)
-$1.5B
Buybacks (2023)
-$2.0B
Buybacks (2024)
-$1.7B
Buybacks (2025)
-$1.0B
Buyback Yield
~0.2%
Acquisitions (2022)
-$0.8B
Acquisitions (2023)
-$1.2B
Acquisitions (2024)
-$20.5B
Acquisitions (2025)
-$5.4B
Cerevel Therapeutics Acquisition
~$8.7B
Recommendation
HOLD / Accumulate on weakness
Strengths
Concerns
AbbVie has successfully transitioned from Humira dependence (now <10% of revenue) to Skyrizi/Rinvoq-driven growth, posting 8.6% revenue growth to $61.16B in 2025 with ~70% gross margins. The stock trades at a deceptive 74.9x trailing P/E due to $5.1B in special charges and a 35.8% tax rate, but the forward P/E of 16.3x and PEG of 0.41 reveal genuine value; normalized EPS power is ~$16+. With $17.8B in annual FCF supporting the 2.67% dividend and manageable 3.5x leverage, the fundamentals support HOLD/accumulate on weakness to $225-$245.
Macro: Supportive but not euphoric — exactly the regime where high-quality compounders like ABBV tend to outperform. Fed on hold with 85% odds of zero cuts in 2026; Polymarket recession odds at just 8% by YE 2026. Treasury expanding long-bond buybacks, easing long-end yields in a bull-steepening shape that favors quality duration. Tariff/policy noise is low-impact for ABBV's domestic-revenue-heavy model. Biopharma sector participating in the bid for defensive growth.